Loading
Everything OnCo dates to 2030: 4 entries, 3 expected dates and 1 landmark. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
4 dated entries in OnCo fall in 2030: 3 expected dates and 1 landmark.
Of those, 2 to the day, 1 to the month and 1 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Hodgkin lymphoma. RADAR (NCT04685616, 1,042 estimated participants) replaces bleomycin with brentuximab vedotin and omits radiotherapy entirely after a Deauville score of 1 to 3; t...
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Estimated primary completion date on ClinicalTrials.gov.
Watch item on the Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific anti...
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...